News
Zacks Investment Research on MSN2d
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseThe market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...
Zacks Investment Research on MSN2d
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...
Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...
Molina cuts 2025 earnings outlook again on ACA, Medicaid pressures The California-based insurer outlined its plans to survive what CEO Joe Zubretsky deemed a “season of great uncertainty.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback